Phathom Pharmaceuticals, Inc.
Financials
Valuation Metrics
Phathom Pharmaceuticals, Inc.'s Market Cap is $597M. At end of 2025 it was $1.21B. Ranked #2714 of 3,121 in US market (top 87%), #1170 of 1,463 on NASDAQ (top 80%), #214 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 80%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $597M | US#2,714/3,121 Sec#214/266 |
| Revenue | $240M | US#2,534/3,121 Sec#104/266 |
| Net Income | $-99M | US—/3,121 Sec—/266 |
| Total Assets | $327M | US#2,899/3,121 Sec#204/266 |
| Net Assets | $-344M | US#3,011/3,121 Sec#263/266 |
| Employees | 371 | US#2,362/3,121 Sec#99/266 |
| Value | ||
| P/S | 2.49x | US#1,533/3,121 Sec#40/266 |
| FCF Yield | -6.15% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROA | -30.29% | US#2,889/3,121 Sec#156/266 |
| Op. Margin | -16.96% | US#2,587/3,121 Sec#98/266 |
| Revenue Growth | 110.16% | US#87/3,121 Sec#31/266 |
| Financial Health | ||
| Total Debt | $167M | US#2,303/3,121 Sec#99/266 |
| FCF | $-37M | US#2,490/3,121 Sec#105/266 |
| Cash | $182M | US#1,808/3,121 Sec#117/266 |
| Current Ratio | 1.92x | US#1,299/3,121 Sec#225/266 |
| Performance | ||
| 1Y Return | -36.34% | US#2,615/3,121 Sec#225/266 |
| 1M Return | -19.74% | US#2,866/3,121 Sec#227/266 |
| From 52W High | -59.15% | US#2,882/3,121 Sec#232/266 |
| 1Y MDD | -58.63% | US#2,718/3,121 Sec#206/266 |
| Trading | ||
| Volume | 1,161,066 shares | US#1,218/3,121 Sec#127/266 |
| Trading Value | $9M | US#2,370/3,121 Sec#194/266 |
| Per Share | ||
| EPS | $-1.24 | US—/3,121 Sec—/266 |
| BPS | $-4.32 | US—/3,121 Sec—/266 |
Company Info
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.